Clinical Trial Update: Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 study of brigatinib in Japanese participants with ALK-positive non-small cell lung cancer has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Brigatinib (brigatinib)

Snippet

Sponsor: Takeda | Conditions: ALK-positive Advanced NSCLC | Phase 2 | Status: COMPLETED | Results posted: 2021-12-14